One outlet tested a headset. The other interviewed a podcast host.
A clinical trial of Cognito Therapeutics' Spectris headset — a device that delivers flickering light and rhythmic sound to stimulate gamma brainwaves — produced mixed results, according to a new study covered by the Times. Bloomberg's contribution was a video interview with former UK Prime Minister David Cameron about his Alzheimer's podcast. Two outlets, one topic, zero overlap in what they chose to report.
Alzheimer's treatment shows mixed results in new study
2 sources · hover a dot to see coverage
What happened
A new study examined Cognito Therapeutics' Spectris headset, which uses audiovisual stimulation to induce gamma-frequency brainwave responses, on the theory that this may slow neurological decline in Alzheimer's patients. The New York Times reported the results as mixed. Bloomberg published a video interview with David Cameron, who hosts a podcast called "Ending Alzheimer's," in which he discussed his personal connection to the disease and what he described as an increasingly bright future for treatment. The two pieces share a subject in name only. That is the wire version. Two outlets have it, and they are covering entirely different things.
The Times covered the science; Bloomberg covered the celebrity
The Times piece engages directly with the clinical question: does a headset delivering light and sound at gamma frequencies produce measurable neurological benefit? The framing — "intriguing approach" with "mixed results" — signals cautious scientific journalism. Bloomberg's piece does not touch the trial. It is a promotional interview with a former head of government who hosts a podcast. Cameron's presence lends the Alzheimer's conversation visibility, but the Bloomberg segment offers no data, no researchers, and no findings. The two pieces cannot be read together to form a more complete picture because they are not covering the same story.
What one side told you that the other didn't
The trial results exist. Only one outlet reported them.
The Spectris trial is the news. Mixed clinical results from a device targeting one of the most treatment-resistant diseases in medicine is a story with stakes. The Times covered it. Bloomberg ran a celebrity interview instead. A reader who saw only Bloomberg's piece would have no idea a clinical study had just published, and a reader who saw only the Times would have no idea David Cameron was involved in Alzheimer's advocacy. Neither piece is wrong. But the gap between them is the whole shape of how health journalism works: science on one side, access on the other.
See how outlets across the political spectrum framed this differently — and what each side left out.